Analysts' Actions: ABBV BMY CHH OC TROW

TheStreet Staff

NEW YORK (TheStreet) -- CHANGE IN RATINGS

AllianceBernstein was downgraded to hold at TheStreet Ratings.

Abbvie was upgraded at BMO Capital to outperform from market perform. $55 price target. Humira can drive impressive growth over the coming quarters, BMO Capital said.

Bristol-Myers was upgraded at Morgan Stanley to overweight from equal-weight. $60 price target. Estimates also raised, as cancer drugs should drive growth, Morgan Stanley said.

Choice Hotels was downgraded at Robert Baird to underperform from neutral. Valuation call, based on the premium to its peers, despite a slower growth model, Robert Baird said.

Choice Hotels was upgraded at Credit Suisse to neutral from underperform. $45 price target. Company is positioned well for the current lodging cycle, Credit Suisse said.

Graco was downgraded at Oppenheimer to perform from outperform. Company has limited earnings upside potential, Oppenheimer said.

Host Hotels was downgraded at Wells Fargo to market perform from outperform. Group demand outlook is softening, Wells Fargo said.

Lear was downgraded at Deutsche Bank to hold from buy. Valuation call, based on an $83 price target, Deutsche Bank said.

Owens Corning was downgraded to hold from buy at Keybanc. Consensus earnings expectations appear too high, Keybanc said.

Owens Corning was downgraded at Bank of America/Merrill Lynch to neutral. Valuation call, based on a $40 price target, Owens Corning said. Estimates were also cut.

Patterson-UTI was upgraded at Goldman Sachs to neutral from sell. $25 price target. Valuation call, as the stock has lagged its peers in recent months, Goldman Sachs said.

Royal Caribbean was upgraded to buy at TheStreet Ratings.

Transocean was downgraded at Goldman Sachs to sell from neutral. Valuation call, based on a $50 price target, Goldman said.

T. Rowe Price was upgraded at UBS to buy from neutral. Estimates were also lifted. Outflows from the international portfolio are slowing and company is well-positioned to benefit from increasing industry inflows of active equity products, UBS said. $90 price target.

Stock Comments / EPS Changes

Aon estimates, price target were increased at Barclays. Driven by upside potential in health exchanges and share buybacks, Barclays said. $82 price target and equal-weight rating.

Bemis estimates, price target were lowered at Jefferies. Limited upside in growth and cost-savings winding down, Jefferies said. $37 price target and hold rating.

Bristol-Myers was added to the US Focus List at Credit Suisse. Company should benefit from growth in the immuno-oncology market, Credit Suisse said. $55 price target.

City National estimates, price target were increased at Jefferies. Company raised its estimates into next year, Jefferies said. Driven by strong cost control and expansion of loan book, Jefferies said. $69 price target and hold rating.

DuPont Fabros estimates, price target were increased at Jefferies. DFT lifted its estimates across the board, Jefferies said. Two upcoming product deliveries and good leasing momentum, Jefferies said. $31 price target and buy rating.

DTE Energy estimates, price target were increased at Barclays. DTE lifted its estimates, Barclays said. Better O&M performance and higher gas midstream expectations. $72 price target and equal-weight rating.

Facebook estimates, price target were increased at Credit Suisse. Shares are now seen reaching $61. Estimates were also increased, given higher mobile app install adds, Credit Suisse said. Neutral rating.

Starwood estimates, price target were increased at BMO Capital. Shares are now seen reaching $75. Estimates were also increased, given the company's new guidance, BMO Capital said. Market Perform rating.

Lear estimates, price target were increased at Keybanc. Estimates were rasied through 2014. Sales and margins can continue to improve, Keybanc said. Buy rating and new $97 price target.

Lear estimates, price target were at Jefferies. LEA lifted its estimates, Jefferies said. The company exceeded margin expectations in electrical business, Jefferies also said. $92 price target and buy rating.

MasterCard estimates, price target were increased at Barclays. MA lifted its estimates, according to Barclays. Strong secular growth trends, margin expansion opportunities and rebates/incentives are driving estimate changes, Barclays said. $830 price target and Overweight rating.

Moody's estimates were lowered at UBS. Higher rates led to slowdown in investment-grade and high-yield issuance, UBS said. $73 price target and neutral rating.

3M estimates, price target were increased at Credit Suisse. Estimates were boosted through 2015. Company is buying back more stock and has a pension tailwind, Credit Suisse said. Neutral rating and new $128 price target.

United Parcel numbers were boosted at Credit Suisse. Shares are now seen reaching $105, according to Credit Suisse. Estimates were also increased, given growth momentum, Credit Suisse said. Outperform rating.

Ventas estimates, price target were lifted at Jefferies. VTR increased its estimates into 2014, Jefferies said. Strong outlook for continued investment activity, Jefferies said. $67 price target and hold rating.

Xcel Energy estimates, price target were increased at UBS. The company is shifting from growth to income, with no additional capex, UBS said. $30 price target and neutral rating.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he thinks could be potentially HUGE winners. Click here to see his holdings for FREE.